OACs can present challenges beyond bleeding risk, including issues with adherence, compliance, and drug interactions. With 70k+ patients implanted, WATCHMAN could be a solution for more of your NVAF patients than you may have thought.
72% reduction in major bleeding events vs. warfarin more than 6 months post procedure1
95% implant success rate2 with a low 1.5% complication rate3—similar to ablation therapy
Lower total out-of-pocket spending vs. warfarin by year 2 and half the cost by year 54
1. Price, MJ, et al. JACC: CV Interv 2015; 8(15): 1925–1932.
PREVAIL findings (3 Years vs. 5)
*2. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.
*Procedural Success defined as deployment and release of the device into the LAA with no leak greater than or equal to 5mm
3. Varosy P et al. JACC 2018; 71(11): A320.
4. Armstrong S, Amorosi SL, Patel P, Erickson GC, Stein K. Medicare Beneficiary Out-of-pocket Spending for Stroke Prevention in Non-valvular Atrial Fibrillation: A Budget Analysis. ISPOR 2015.
Note Estimated costs are based on national averages of 2019 U.S. Medicare rates, and assume a 20% copay for Medicare Part B. These estimates will vary depending upon the patient’s individual healthcare policy. Insurance coverage can vary significantly from one plan to another, even within the same insurance company. We therefore recommend that patients contact their insurance provider directly with questions regarding estimated patient-specific out-of-pocket costs.